Cargando…

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes

AIM: To evaluate the long‐term safety and efficacy of canagliflozin as add‐on therapy in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with teneligliptin monotherapy. METHODS: This open‐label 52‐week study was conducted in Japan. Patients received canagliflozin 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Watanabe, Yumi, Gouda, Maki, Iijima, Hiroaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724659/ https://www.ncbi.nlm.nih.gov/pubmed/28608617 http://dx.doi.org/10.1111/dom.13038

Ejemplares similares

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
por: Harashima, Shin‐ichi, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus
por: Kadowaki, Takashi, et al.
Publicado: (2013)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice
por: Ceriello, Antonio, et al.
Publicado: (2019)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study
por: Cho, Kyu Yong, et al.
Publicado: (2021)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
por: Fushimi, Yoshiro, et al.
Publicado: (2020)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
por: Kumar, Amit, et al.
Publicado: (2019)

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
por: Noda, Tomoho, et al.
Publicado: (2019)

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database
por: Yokote, Koutaro, et al.
Publicado: (2021)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†
por: Inagaki, N, et al.
Publicado: (2013)

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors
por: Nakamaru, Yoshinobu, et al.
Publicado: (2016)

Efficacy and safety of teneligliptin
por: Singh, Awadhesh Kumar
Publicado: (2017)

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2018)

Associations between eating habits and glycemic control and obesity in Japanese workers with type 2 diabetes mellitus
por: Gouda, Maki, et al.
Publicado: (2018)

Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
por: Son, Cheol, et al.
Publicado: (2019)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Teneligliptin in management of type 2 diabetes mellitus
por: Sharma, Surendra Kumar, et al.
Publicado: (2016)

Teneligliptin and “Thorough QTc study”: thorough enough?
por: Ghosal, Samit
Publicado: (2019)

Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with (111)In-labeled exendin-4
por: Hamamatsu, Keita, et al.
Publicado: (2019)

Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Teneligliptin-induced hair loss: A case report
por: Agrawal, Prabhat K., et al.
Publicado: (2020)

Exanthematous Drug Eruption as a Side Effect of Teneligliptin
por: Sunil, Krupa A., et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
por: Adachi, Junichiro, et al.
Publicado: (2017)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
por: Inagaki, Nobuya, et al.
Publicado: (2021)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
por: Okuda, Yoshinori, et al.
Publicado: (2016)

Therapeutic Effect of Teneligliptin in Drug-Induced Nephrotoxicity: An In-Vitro Study
por: Becerir, Tülay, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jevtq2r67e4k5jr1q6ds3sj7r